Charles Schwab
XLO icon

Charles Schwab’s Xilio Therapeutics XLO Stock Holding History

Charles Schwab’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-852
Closed -$11.3K – 3613
2024
Q2 		$11.3K Hold
852
– – ﹤0.01% 3608
2024
Q1 		$12.9K Hold
852
– – ﹤0.01% 3454
2023
Q4 		$6.56K Hold
852
– – ﹤0.01% 3535
2023
Q3 		$25.2K Hold
852
– – ﹤0.01% 3488
2023
Q2 		$31.2K Buy
+852
New +$36.2K ﹤0.01% 3501
2022
Q2 		– Sell
-1,150
Closed -$114K – 3654
2022
Q1 		$114K Hold
1,150
– – ﹤0.01% 3394
2021
Q4 		$258K Buy
+1,150
New +$274K ﹤0.01% 3311

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab's XLO Position: Q3 2024 in Review

Charles Schwab sold out of Xilio Therapeutics (XLO) in Q3 2024, closing a stake of 852 shares — an estimated $11.3K sold.

Charles Schwab first reported a position in XLO in Q4 2021 and held it in 7 quarters. The position peaked at $258K in Q4 2021. 33 funds tracked by Wall St. Rank hold XLO as of Q3 2024.

  • Charles Schwab reported no remaining Xilio Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 852 Xilio Therapeutics shares in Q3 2024, an estimated $11.3K.
  • Charles Schwab first reported a position in Xilio Therapeutics in Q4 2021 and held it in 7 quarters.
  • Charles Schwab's Xilio Therapeutics position peaked at $258K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.